Jürgen Schumacher

SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion.

Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Qiagen SRL is engaged in providing assay technologies. The company is headquartered in Milan, Italy.

Part of Charles River Laboratories International, Inc., NewLab BioQuality AG is a laboratory services provider that specializes in the analysis of biopharmaceutical drugs. The company is based in Erkrath, Germany. The German company was founded by Jürgen Schumacher. Jürgen Schumacher has been the CEO since incorporation. NewLab BioQuality was acquired by Charles River Laboratories International, Inc. on September 09, 2008 for $52.65 million.